Ongoing projects and recently completed projects:

• P20 GM135004-01

Yan (co-PI) and Chesney (co-PI)

02/01/20-01/31/25

COBRE Center for Cancer Immunology and Immunotherapy

• NCI R01 CA272772

Yaddanapudi (PI), Role: co-investigator

04/01/23 – 03/31/28

Identifying and targeting a novel mechanism of chemotherapy-induced immunotherapeutic resistance in NSCLC                                                 

• NCI R21 CA277314

Yaddanapudi (PI), Role: co-investigator

02/17/23 – 01/31/25

A Stem Cell-Based Exosomal Vaccine for the Prevention of Cancer

• NCI R21 CA245560

Yaddanapudi (PI), Role: co-investigator

01/07/20–03/30/23

Overcoming Resistance to Cancer Immunotherapy by Targeting MDSC-Derived Adenosine                                                                                   

• NIH 3P20GM135004-05S1

Chesney (co-PI) and Yan (co-PI)

07/01/24-01/31/25

Collaborative Team Science to Delineate the Mechanisms Underlying Primary Resistance or Response to Tumor-infiltrating Lymphocyte   Therapy in Cancer Patients.

• NCT04614103

Chesney (PI)

05/07/21-12/31/26

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with NSCLC

• NCT03108495                                                                                                                                               

Chesney (PI)

06/22/17-12/31/30

Study of LN-145, Autologous Tumor Infiltrating Lymphocytes for Patients with Cervical Carcinoma

• NCT05361174

Chesney (PI)

07/20/22-06/30/27A Phase 1/2, Open-label Study of PD1 Knock-out Tumor-infiltrating Lymphocytes (IOV-4001) in Participants with Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

• NCT06060613

Chesney (PI)

10/25/23-20/30/27A Phase 1/2, Open-Label Study to Investigate the Safety and Efficacy of Membrane-Bound IL15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) In Participants with Advanced Solid Tumors